CN114630839A - 抗ox40抗体及其用途 - Google Patents

抗ox40抗体及其用途 Download PDF

Info

Publication number
CN114630839A
CN114630839A CN202080073615.0A CN202080073615A CN114630839A CN 114630839 A CN114630839 A CN 114630839A CN 202080073615 A CN202080073615 A CN 202080073615A CN 114630839 A CN114630839 A CN 114630839A
Authority
CN
China
Prior art keywords
antibody
cancer
seq
antigen
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080073615.0A
Other languages
English (en)
Inventor
张宏恺
晋瑞娜
王媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nankai University
Original Assignee
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nankai University filed Critical Nankai University
Publication of CN114630839A publication Critical patent/CN114630839A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

新型抗OX40抗体，包含所述抗OX40抗体的组合物，编码所述抗OX40抗体的核酸，制备所述抗OX40抗体的方法，和所述抗OX40抗体的用途。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080073615.0A 2019-12-27 2020-12-28 抗ox40抗体及其用途 Pending CN114630839A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911380303.XA CN113045654A (zh) 2019-12-27 2019-12-27 抗ox40抗体及其用途
CN201911380303X 2019-12-27
PCT/CN2020/140259 WO2021129874A1 (zh) 2019-12-27 2020-12-28 抗ox40抗体及其用途

Publications (1)

Publication Number Publication Date
CN114630839A true CN114630839A (zh) 2022-06-14

Family

ID=76506637

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911380303.XA Pending CN113045654A (zh) 2019-12-27 2019-12-27 抗ox40抗体及其用途
CN202080073615.0A Pending CN114630839A (zh) 2019-12-27 2020-12-28 抗ox40抗体及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911380303.XA Pending CN113045654A (zh) 2019-12-27 2019-12-27 抗ox40抗体及其用途

Country Status (2)

Country Link
CN (2) CN113045654A (zh)
WO (1) WO2021129874A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
CN114591988B (zh) * 2022-03-30 2023-01-13 北京贝来生物科技有限公司 一种激活肿瘤免疫的基因修饰干细胞制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101293917A (zh) * 2008-06-16 2008-10-29 南开大学 与pkr激酶结构域特异性结合的多肽及其应用
WO2018031490A2 (en) * 2016-08-08 2018-02-15 Sorrento Therapeutics, Inc. Anti-ox40 binding proteins
WO2018112346A1 (en) * 2016-12-15 2018-06-21 Abbvie Biotherapeutics Inc. Anti-ox40 antibodies and their uses
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN110003338A (zh) * 2019-04-16 2019-07-12 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
CN110004177A (zh) * 2019-04-22 2019-07-12 中国食品药品检定研究院 一种检测抗ox40抗体的方法及其应用
CN110078825A (zh) * 2019-01-23 2019-08-02 北京天广实生物技术股份有限公司 结合ox40的抗体及其用途
CN110467674A (zh) * 2018-05-11 2019-11-19 上海药明生物技术有限公司 抗ox40的全人抗体及其制备方法和用途
CN110551216A (zh) * 2018-05-31 2019-12-10 信达生物制药(苏州)有限公司 多价抗ox40抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
US11142579B2 (en) * 2017-12-06 2021-10-12 Sorrento Therapeutics, Inc. Variant antibodies that bind OX40

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101293917A (zh) * 2008-06-16 2008-10-29 南开大学 与pkr激酶结构域特异性结合的多肽及其应用
WO2018031490A2 (en) * 2016-08-08 2018-02-15 Sorrento Therapeutics, Inc. Anti-ox40 binding proteins
WO2018112346A1 (en) * 2016-12-15 2018-06-21 Abbvie Biotherapeutics Inc. Anti-ox40 antibodies and their uses
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN110467674A (zh) * 2018-05-11 2019-11-19 上海药明生物技术有限公司 抗ox40的全人抗体及其制备方法和用途
CN110551216A (zh) * 2018-05-31 2019-12-10 信达生物制药(苏州)有限公司 多价抗ox40抗体及其用途
CN110078825A (zh) * 2019-01-23 2019-08-02 北京天广实生物技术股份有限公司 结合ox40的抗体及其用途
CN110003338A (zh) * 2019-04-16 2019-07-12 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
CN110004177A (zh) * 2019-04-22 2019-07-12 中国食品药品检定研究院 一种检测抗ox40抗体的方法及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
SANDRINE ASPESLAGH等: "Rationale for anti-OX40 cancer immunotherapy", EUROPEAN JOURNAL OF CANCER, vol. 52, 31 January 2016 (2016-01-31), pages 50 - 66, XP029373119, DOI: 10.1016/j.ejca.2015.08.021 *
WEIYI PENG 等: "Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma", CLIN CANCER RES, vol. 25, no. 21, 1 August 2019 (2019-08-01), pages 6406, XP055823827, DOI: 10.1158/1078-0432.CCR-19-1259 *
候小娟等: "抗人OX40单克隆抗体的制备和初步鉴定", 生物技术通讯, vol. 28, no. 3, 30 May 2017 (2017-05-30), pages 242 - 248 *

Also Published As

Publication number Publication date
CN113045654A (zh) 2021-06-29
WO2021129874A1 (zh) 2021-07-01
TW202130661A (zh) 2021-08-16

Similar Documents

Publication Publication Date Title
JP7450592B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP2019526622A (ja) がん治療用の抗Ｓｉｇｌｅｃ−７抗体
TWI824217B (zh) 抗ox40抗體及其用途
WO2021129874A1 (zh) 抗ox40抗体及其用途
JP7280387B2 (ja) 抗原結合タンパク質
TWI841816B (zh) 抗ox40抗體及其用途
TW202216194A (zh) 包含抗ｃｄ１３７抗體之組合療法
CN113226369A (zh) 给药
WO2023275616A1 (en) Anti-ox40 monoclonal antibody and methods of use thereof
KR20230154315A (ko) 항체의 신규한 조합물 및 이의 용도
TW202304979A (zh) 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2021046293A1 (en) Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination